SEC filing summary
Registrant: GX Acquisition Corp., not Celularity Inc. The supplied filing is GX Acquisition Corp.’s unaudited Form 10-Q for the quarter ended September 30, 2020. GX was a blank-check company seeking a business combination; it had not begun operating activities or generated operating revenue.
Financial results and position
- Revenue and margins: No operating revenue; margins are not meaningful. The company reported operating costs of $208,305 for Q3 2020 and $658,177 for the first nine months of 2020.
- Profit: Q3 2020 net loss was $37,524, compared with net income of $1,121,167 in Q3 2019. Nine-month 2020 net income was $843,575, down from $1,755,706 in 2019. Results principally reflected interest and unrealized gains on trust investments, offset by expenses and taxes.
- Cash flow: Operating activities used $938,713 in the first nine months of 2020, versus $874,029 in the comparable 2019 period. Cash outside the trust account declined from $917,007 at year-end 2019 to $454,497 at September 30, 2020.
- Liquidity and assets: The trust account held $291,844,594, primarily in short-term U.S. Treasury securities. Working capital was $490,819. The company said trust funds were intended primarily for a business combination, subject to permitted tax withdrawals.
- Debt and obligations: No long-term debt was reported. Current liabilities were $141,314, and a $10,812,500 deferred underwriting fee was payable only if a business combination closed. The company also had recurring administrative and consulting fees.
- Equity: Stockholders’ equity was $5,000,004; 27,239,680 Class A shares, with a redemption value of $276,407,327, were presented as temporary equity outside stockholders’ equity.
Changes and outlook
- Q3 results shifted from prior-year net income to a small net loss, as trust interest income fell sharply to $100,729 from $1,679,863. Nine-month net income also declined year over year, while operating costs increased to $658,177 from $317,375.
- Management said additional capital might be needed for working capital and transaction costs. Sponsor, director, and officer loans were possible but not committed; financing availability was not assured. Management disclosed substantial doubt about the company’s ability to continue as a going concern through May 23, 2021 if no business combination was completed.
- The company had until May 23, 2021 to complete a business combination; otherwise, it was required to cease operations and redeem public shares, subject to the filing’s terms. No operating forecast or specific financial guidance was provided.
- Risks included inability to obtain financing or complete a transaction before the deadline, potential dilution or debt from a transaction, possible negative interest rates reducing trust value, and uncertainty about the Sponsor’s ability to meet its trust-account indemnity obligations.
Important facts to verify
- Confirm the intended company: this filing is for GX Acquisition Corp., not Celularity Inc.
- Verify the business-combination status and any later filings or transaction announcements; this report disclosed no subsequent event requiring adjustment or disclosure.
- Assess available non-trust cash, potential financing needs, the May 23, 2021 deadline, and the going-concern warning.
- Review the redemption terms, trust-account balance, deferred underwriting fee, and potential dilution or warrant effects in any proposed transaction.